TriangleNCT03011372 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 2513 days (120 21-day treatment cycles)
What was measured
Overall survival was defined as as the time from the first day of taking study drug until death due to any cause
Analysis population: Full Efficacy-Evaluable Population. Confidence intervals were calculated using the Brookmeyer and Crowley's method. Participants without death observed at the time of the analysis were censored at the last date known to be alive.
Groups in this outcome
Pemigatinib 13.5 mg
Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.
| Group | Source count |
|---|---|
| Pemigatinib 13.5 mg | 45 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pemigatinib 13.5 mg | NA | Not reported | 54.74 | NA | The median and the upper limit of the confidence interval were not estimable because too few participants died. |
Complete source fields
- classes
- categories
- measurements
- comment
- The median and the upper limit of the confidence interval were not estimable because too few participants died.
- group Id
- OG000
- lower Limit
- 54.74
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 45
- units
- Participants
- description
- Overall survival was defined as as the time from the first day of taking study drug until death due to any cause
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.
- id
- OG000
- title
- Pemigatinib 13.5 mg
- param Type
- MEDIAN
- population Description
- Full Efficacy-Evaluable Population. Confidence intervals were calculated using the Brookmeyer and Crowley's method. Participants without death observed at the time of the analysis were censored at the last date known to be alive.
- reporting Status
- POSTED
- time Frame
- up to 2513 days (120 21-day treatment cycles)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice